SAR 43.0
(-0.12%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 14.07 Million SAR | 3.86% |
2022 | 13.55 Million SAR | 20.9% |
2021 | 11.2 Million SAR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 4.09 Million SAR | 0.0% |
2024 Q1 | 4.09 Million SAR | 0.42% |
2023 Q3 | 4.07 Million SAR | -10.91% |
2023 Q4 | 4.07 Million SAR | 0.0% |
2023 FY | 14.07 Million SAR | 3.86% |
2023 Q2 | 4.57 Million SAR | 0.0% |
2023 Q1 | 4.57 Million SAR | 3.08% |
2022 FY | 13.55 Million SAR | 20.9% |
2022 Q4 | 4.43 Million SAR | 0.0% |
2021 FY | 11.2 Million SAR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 207.04 Million SAR | 93.203% |
Al-Dawaa Medical Services Company | 2.06 Billion SAR | 99.318% |
Nahdi Medical Company | 3.52 Billion SAR | 99.6% |
Almujtama Alraida Medical Co. | 129.2 Million SAR | 89.107% |